Selected research
Market Structure
Global Veterinary Infectious Diseases Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Veterinary Infectious Diseases Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Veterinary Infectious Diseases Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Veterinary Infectious Diseases Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Veterinary Infectious Diseases Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Veterinary Infectious Diseases Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Veterinary Infectious Diseases Therapeutics include Sanofi, Merck, Virbac, Pfizer Animal Health, Novartis Animal Health, Elanco Animal Health, Elanco Animal Health, Dechra Animal Health and Ceva Sante Animale, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Veterinary Infectious Diseases Therapeutics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Veterinary Infectious Diseases Therapeutics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Veterinary Infectious Diseases Therapeutics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Veterinary Infectious Diseases Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
Veterinary Infectious Diseases Therapeutics Segment by Company
Sanofi
Merck
Virbac
Pfizer Animal Health
Novartis Animal Health
Elanco Animal Health
Elanco Animal Health
Dechra Animal Health
Ceva Sante Animale
Boehringer Ingelheim Vetmedica
Veterinary Infectious Diseases Therapeutics Segment by Type
Amebicides
Anthelmintics
Antifungal
Antibiotics
Antiviral
Veterinary Infectious Diseases Therapeutics Segment by Application
Swine
Cow
Cat
Horse
Chicken
Dog
Other
Veterinary Infectious Diseases Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Veterinary Infectious Diseases Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Veterinary Infectious Diseases Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Veterinary Infectious Diseases Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Veterinary Infectious Diseases Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Veterinary Infectious Diseases Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Veterinary Infectious Diseases Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Veterinary Infectious Diseases Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Amebicides
- Anthelmintics
- Antifungal
- Antibiotics
- Antiviral
Applications
- Swine
- Cow
- Cat
- Horse
- Chicken
- Dog
- Other
Companies covered
- Sanofi
- Merck
- Virbac
- Pfizer Animal Health
- Novartis Animal Health
- Elanco Animal Health
- Elanco Animal Health
- Dechra Animal Health
- Ceva Sante Animale
- Boehringer Ingelheim Vetmedica
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Veterinary Infectious Diseases Therapeutics Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Veterinary Infectious Diseases Therapeutics Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Veterinary Infectious Diseases Therapeutics Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Veterinary Infectious Diseases Therapeutics Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Veterinary Infectious Diseases Therapeutics Market Dynamics
- 2.1 Veterinary Infectious Diseases Therapeutics Industry Trends
- 2.2 Veterinary Infectious Diseases Therapeutics Industry Drivers
- 2.3 Veterinary Infectious Diseases Therapeutics Industry Opportunities and Challenges
- 2.4 Veterinary Infectious Diseases Therapeutics Industry Restraints
3 Veterinary Infectious Diseases Therapeutics Market by Manufacturers
- 3.1 Global Veterinary Infectious Diseases Therapeutics Revenue by Manufacturers (2021-2026)
- 3.2 Global Veterinary Infectious Diseases Therapeutics Sales by Manufacturers (2021-2026)
- 3.3 Global Veterinary Infectious Diseases Therapeutics Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Veterinary Infectious Diseases Therapeutics Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Veterinary Infectious Diseases Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Veterinary Infectious Diseases Therapeutics Manufacturers, Product Type & Application
- 3.7 Global Veterinary Infectious Diseases Therapeutics Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Veterinary Infectious Diseases Therapeutics Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Veterinary Infectious Diseases Therapeutics Players Market Share by Revenue in 2025
- 3.8.3 2025 Veterinary Infectious Diseases Therapeutics Tier 1, Tier 2, and Tier 3
4 Veterinary Infectious Diseases Therapeutics Market by Type
- 4.1 Veterinary Infectious Diseases Therapeutics Type Introduction
- 4.1.1 Amebicides
- 4.1.2 Anthelmintics
- 4.1.3 Antifungal
- 4.1.4 Antibiotics
- 4.1.5 Antiviral
- 4.2 Global Veterinary Infectious Diseases Therapeutics Sales by Type
- 4.2.1 Global Veterinary Infectious Diseases Therapeutics Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Veterinary Infectious Diseases Therapeutics Sales by Type (2021-2032)
- 4.2.3 Global Veterinary Infectious Diseases Therapeutics Sales Market Share by Type (2021-2032)
- 4.3 Global Veterinary Infectious Diseases Therapeutics Revenue by Type
- 4.3.1 Global Veterinary Infectious Diseases Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Veterinary Infectious Diseases Therapeutics Revenue by Type (2021-2032)
- 4.3.3 Global Veterinary Infectious Diseases Therapeutics Revenue Market Share by Type (2021-2032)
5 Veterinary Infectious Diseases Therapeutics Market by Application
- 5.1 Veterinary Infectious Diseases Therapeutics Application Introduction
- 5.1.1 Swine
- 5.1.2 Cow
- 5.1.3 Cat
- 5.1.4 Horse
- 5.1.5 Chicken
- 5.1.6 Dog
- 5.1.7 Other
- 5.2 Global Veterinary Infectious Diseases Therapeutics Sales by Application
- 5.2.1 Global Veterinary Infectious Diseases Therapeutics Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Veterinary Infectious Diseases Therapeutics Sales by Application (2021-2032)
- 5.2.3 Global Veterinary Infectious Diseases Therapeutics Sales Market Share by Application (2021-2032)
- 5.3 Global Veterinary Infectious Diseases Therapeutics Revenue by Application
- 5.3.1 Global Veterinary Infectious Diseases Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Veterinary Infectious Diseases Therapeutics Revenue by Application (2021-2032)
- 5.3.3 Global Veterinary Infectious Diseases Therapeutics Revenue Market Share by Application (2021-2032)
6 Global Veterinary Infectious Diseases Therapeutics Sales by Region
- 6.1 Global Veterinary Infectious Diseases Therapeutics Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Veterinary Infectious Diseases Therapeutics Sales by Region (2021-2032)
- 6.2.1 Global Veterinary Infectious Diseases Therapeutics Sales by Region (2021-2026)
- 6.2.2 Global Veterinary Infectious Diseases Therapeutics Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Veterinary Infectious Diseases Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Veterinary Infectious Diseases Therapeutics Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Veterinary Infectious Diseases Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Veterinary Infectious Diseases Therapeutics Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Veterinary Infectious Diseases Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Veterinary Infectious Diseases Therapeutics Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Veterinary Infectious Diseases Therapeutics Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Veterinary Infectious Diseases Therapeutics Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Veterinary Infectious Diseases Therapeutics Revenue by Region
- 7.1 Global Veterinary Infectious Diseases Therapeutics Revenue by Region
- 7.1.1 Global Veterinary Infectious Diseases Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Veterinary Infectious Diseases Therapeutics Revenue by Region (2021-2026)
- 7.1.3 Global Veterinary Infectious Diseases Therapeutics Revenue by Region (2027-2032)
- 7.1.4 Global Veterinary Infectious Diseases Therapeutics Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Veterinary Infectious Diseases Therapeutics Revenue (2021-2032)
- 7.2.2 North America Veterinary Infectious Diseases Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Veterinary Infectious Diseases Therapeutics Revenue (2021-2032)
- 7.3.2 Europe Veterinary Infectious Diseases Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Veterinary Infectious Diseases Therapeutics Revenue (2021-2032)
- 7.4.2 Asia-Pacific Veterinary Infectious Diseases Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Veterinary Infectious Diseases Therapeutics Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Veterinary Infectious Diseases Therapeutics Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Company Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sanofi Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 Merck
- 8.2.1 Merck Company Information
- 8.2.2 Merck Business Overview
- 8.2.3 Merck Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Merck Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.2.5 Merck Recent Developments
- 8.3 Virbac
- 8.3.1 Virbac Company Information
- 8.3.2 Virbac Business Overview
- 8.3.3 Virbac Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Virbac Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.3.5 Virbac Recent Developments
- 8.4 Pfizer Animal Health
- 8.4.1 Pfizer Animal Health Company Information
- 8.4.2 Pfizer Animal Health Business Overview
- 8.4.3 Pfizer Animal Health Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Pfizer Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.4.5 Pfizer Animal Health Recent Developments
- 8.5 Novartis Animal Health
- 8.5.1 Novartis Animal Health Company Information
- 8.5.2 Novartis Animal Health Business Overview
- 8.5.3 Novartis Animal Health Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Novartis Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.5.5 Novartis Animal Health Recent Developments
- 8.6 Elanco Animal Health
- 8.6.1 Elanco Animal Health Company Information
- 8.6.2 Elanco Animal Health Business Overview
- 8.6.3 Elanco Animal Health Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Elanco Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.6.5 Elanco Animal Health Recent Developments
- 8.7 Elanco Animal Health
- 8.7.1 Elanco Animal Health Company Information
- 8.7.2 Elanco Animal Health Business Overview
- 8.7.3 Elanco Animal Health Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Elanco Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.7.5 Elanco Animal Health Recent Developments
- 8.8 Dechra Animal Health
- 8.8.1 Dechra Animal Health Company Information
- 8.8.2 Dechra Animal Health Business Overview
- 8.8.3 Dechra Animal Health Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Dechra Animal Health Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.8.5 Dechra Animal Health Recent Developments
- 8.9 Ceva Sante Animale
- 8.9.1 Ceva Sante Animale Company Information
- 8.9.2 Ceva Sante Animale Business Overview
- 8.9.3 Ceva Sante Animale Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Ceva Sante Animale Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.9.5 Ceva Sante Animale Recent Developments
- 8.10 Boehringer Ingelheim Vetmedica
- 8.10.1 Boehringer Ingelheim Vetmedica Company Information
- 8.10.2 Boehringer Ingelheim Vetmedica Business Overview
- 8.10.3 Boehringer Ingelheim Vetmedica Veterinary Infectious Diseases Therapeutics Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Boehringer Ingelheim Vetmedica Veterinary Infectious Diseases Therapeutics Product Portfolio
- 8.10.5 Boehringer Ingelheim Vetmedica Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Veterinary Infectious Diseases Therapeutics Value Chain Analysis
- 9.1.1 Veterinary Infectious Diseases Therapeutics Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Veterinary Infectious Diseases Therapeutics Production Mode & Process
- 9.2 Veterinary Infectious Diseases Therapeutics Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Veterinary Infectious Diseases Therapeutics Distributors
- 9.2.3 Veterinary Infectious Diseases Therapeutics Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst